TD Cowen Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Key Points

• TD Cowen has raised its price target for Insmed (NASDAQ:INSM) from $154.00 to $193.00, indicating a potential upside of 31.20%.
• Insmed has received a majority of "buy" ratings from equity analysts, with an average consensus target price of $145.69.
• In its most recent earnings report, Insmed missed EPS estimates but reported a revenue increase of 18.9% year-over-year.

Insmed (NASDAQ:INSM - Get Free Report) had its target price boosted by stock analysts at TD Cowen from $154.00 to $193.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price target suggests a potential upside of 31.20% from the stock's current price.

Several other equities research analysts also recently commented on INSM. HC Wainwright upped their price target on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. The Goldman Sachs Group increased their price target on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Royal Bank Of Canada increased their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. William Blair assumed coverage on shares of Insmed in a research note on Wednesday, August 20th. They set an "outperform" rating on the stock. Finally, UBS Group raised their target price on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Eighteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $145.69.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $0.17 during trading on Thursday, reaching $147.11. The company had a trading volume of 264,371 shares, compared to its average volume of 2,720,866. The firm's fifty day moving average is $130.41 and its 200 day moving average is $97.89. The firm has a market capitalization of $31.10 billion, a PE ratio of -25.81 and a beta of 1.03. Insmed has a twelve month low of $60.40 and a twelve month high of $149.08. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company's revenue was up 18.9% on a year-over-year basis. During the same period in the prior year, the company posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Insmed will post -4.56 EPS for the current year.

Insider Buying and Selling

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This trade represents a 67.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $128.40, for a total transaction of $881,466.00. Following the transaction, the chief executive officer directly owned 233,924 shares of the company's stock, valued at $30,035,841.60. The trade was a 2.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 277,332 shares of company stock worth $33,842,327. 3.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Institutional investors have recently added to or reduced their stakes in the company. Hilltop National Bank bought a new position in Insmed during the 2nd quarter valued at about $28,000. ORG Partners LLC raised its stake in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Insmed in the second quarter worth about $33,000. Cullen Frost Bankers Inc. raised its stake in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the last quarter. Finally, LRI Investments LLC bought a new stake in shares of Insmed during the second quarter worth approximately $59,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.